Ajanta African Business Offsets US And Asia Pressures
Company Netted Overall Growth Of 12% In Q3
Executive Summary
Despite facing adversity in the US and Asian markets, Indian firm Ajanta Pharma was ultimately able to deliver respectable growth across Q3 as its African branded generics business thrived.